Neurolens Raises $67 Million Investment to Develop New Products and Accelerate Adoption
Neurolens announced completion of a $67 million financing to fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens.
The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wace, and existing investors including Bluestem Capital.
"While we have grown tenfold in the past 3 years, the unmet patient need remains massive," said Pierre Bertrand, Neurolens CEO. "Nearly 6 out of 10 Americans are reporting daily symptoms of Digital Vision Syndrome, and we are excited to continue bringing solutions to independent optometry to meet their needs. We are grateful to see both current and new investors embrace our mission to transform eye care beyond visual acuity."
"Neurolens offers a remarkable solution to address the widespread problems that patients experience due to DVS. We are pleased to partner with Neurolens to support its continued growth." said Dr. Eric Bednarski, Partner at MVM.
The investment follows two recent announcements. In August, Neurolens had been recognized as the 28th fastest growing health care company on the annual Inc. 5000 list. Earlier in August, Neurolens released the results of a parallel arm study evaluating reading speed at baseline. The study revealed that after 7 days of lens wear, the average improvement in reading speed with Neurolenses was almost 70% higher than the improvement seen with other premium lens designs, according to Neurolens.
To learn more about Neurolens, visit https://www.neurolens.com.